Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melvin Lafeber

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
European Journal of Preventive Cardiology|July 24, 2018
Combined use of polypill components in patients with type 2 diabetes mellitusVivi E Janssen, Frank L Visseren, Anthonius de Boer, et al.
European Journal of Preventive Cardiology|February 6, 2013
The evening versus morning polypill utilization study: the TEMPUS rationale and designMelvin Lafeber, Diederick E Grobbee, Michiel L Bots, et al.
American Heart Journal|July 31, 2013
The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery diseaseMelvin Lafeber, Wilko Spiering, Yolanda van der Graaf, et al.
Lancet (London, England)|June 11, 2026
Challenges in assessing statin-associated adverse eventsMarte F van der Bijl, Ruben J M Mijnster, P Hugo M van der Kuy, et al.
BMJ Open|June 25, 2026
N=1-studies In Statin-intolerance; Objectifying Nocebo Effects (NISONE): a study protocol for a randomised controlled trial assessing the implementability of N=1-studies to promote the use of statinsRuben Mijnster, Jeanine Roeters van Lennep, Wim Rietdijk, et al.
Journal of Hypertension|May 7, 2020
Angiotensin-converting enzyme-2 in SARS-CoV-2 infection: good or bad?Jorie Versmissen, Koen Verdonk, Melvin Lafeber, et al.
European Journal of Preventive Cardiology|April 25, 2017
Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high riskMelvin Lafeber, Wilko Spiering, Frank Lj Visseren, et al.
Atherosclerosis|June 1, 2025
Efficacy and safety of PCSK9 monoclonal antibodies in older patients: A real-world registryRuben J M Mijnster, Janneke W C M Mulder, Annette M H Galema-Boers, et al.
British Journal of Clinical Pharmacology|January 28, 2021
No association between use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) studyRoos S G Sablerolles, Freija E F Hogenhuis, Melvin Lafeber, et al.
Clinical and Translational Science|August 13, 2025
Recommendations for (Pharmaco)Genetic Sampling in Patients Following Allogeneic Hematopoietic Stem Cell TransplantationAnniek Bokma, Maja Matic, Arwin Ralf, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
European Journal of Preventive Cardiology|July 24, 2018
Combined use of polypill components in patients with type 2 diabetes mellitusVivi E Janssen, Frank L Visseren, Anthonius de Boer, et al.
European Journal of Preventive Cardiology|February 6, 2013
The evening versus morning polypill utilization study: the TEMPUS rationale and designMelvin Lafeber, Diederick E Grobbee, Michiel L Bots, et al.
American Heart Journal|July 31, 2013
The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery diseaseMelvin Lafeber, Wilko Spiering, Yolanda van der Graaf, et al.
Lancet (London, England)|June 11, 2026
Challenges in assessing statin-associated adverse eventsMarte F van der Bijl, Ruben J M Mijnster, P Hugo M van der Kuy, et al.
BMJ Open|June 25, 2026
N=1-studies In Statin-intolerance; Objectifying Nocebo Effects (NISONE): a study protocol for a randomised controlled trial assessing the implementability of N=1-studies to promote the use of statinsRuben Mijnster, Jeanine Roeters van Lennep, Wim Rietdijk, et al.
Journal of Hypertension|May 7, 2020
Angiotensin-converting enzyme-2 in SARS-CoV-2 infection: good or bad?Jorie Versmissen, Koen Verdonk, Melvin Lafeber, et al.
European Journal of Preventive Cardiology|April 25, 2017
Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high riskMelvin Lafeber, Wilko Spiering, Frank Lj Visseren, et al.
Atherosclerosis|June 1, 2025
Efficacy and safety of PCSK9 monoclonal antibodies in older patients: A real-world registryRuben J M Mijnster, Janneke W C M Mulder, Annette M H Galema-Boers, et al.
British Journal of Clinical Pharmacology|January 28, 2021
No association between use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) studyRoos S G Sablerolles, Freija E F Hogenhuis, Melvin Lafeber, et al.
Clinical and Translational Science|August 13, 2025
Recommendations for (Pharmaco)Genetic Sampling in Patients Following Allogeneic Hematopoietic Stem Cell TransplantationAnniek Bokma, Maja Matic, Arwin Ralf, et al.
Pageof 4